ライフサイエンスコーパス: costimulator

1 , CD137 (4-1BB), CD134 (OX40), and inducible costimulator.

2 ted the ability of rhIL-4 to act as a T cell costimulator.

3 n containing protein 3, and inducible T-cell costimulator.

4 ulties in classifying it as a coinhibitor or costimulator.

5 riant in ICOS, encoding the inducible T-cell costimulator.

6 s recruited to, and regulates, CD28 as a TCR costimulator.

7 ng both forkhead box protein 3 and inducible costimulator.

8 whether Tim-1 can have a dual function as a costimulator.

9 eplaced by reagents binding inducible T-cell costimulators.

10 ells and does not depend on MHC molecules or costimulators.

11 e lung with elevated expression of inducible costimulator a marker of T cell activation, and of T1/ST

12 Selective inducible costimulator activation (P < .001) was seen in children.

13 t for alloimmunity, including MHC molecules, costimulators, adhesion molecules, cytokines, chemokines

14 To facilitate this type of quantitative costimulator analysis, we developed a novel two-step pro

15 entified TL1A, an endothelium-derived T cell costimulator and a ligand for tumor necrosis factor rece

16 rface Daf protein function respectively as a costimulator and a negative modulator of T cell immunity

17 tudy demonstrates that CD55 acts as a potent costimulator and activator of human naive CD4(+) cells,

18 ation to splenic T cells via an unidentified costimulator and ICAM-1.

19 turation was manifest by marked increases in costimulator and major histocompatibility complex class

20 timulatory domain of TMIGD2, a T and NK cell costimulator, and monoclonal antibodies targeting the Ig

21 D-L2, CD40, CD80, CD86, and inducible T cell costimulator, and of major histocompatibility complex cl

22 n C-X-C chemokine receptor type 5, inducible costimulator, and programmed cell death protein 1 was ex

23 on of live tumor cells to express cytokines, costimulators, and surrogate foreign antigens.

24 We found that both antibody to inducible costimulator (anti-ICOS) and an ICOS-Ig fusion protein s

25 The effects of these costimulators are overlapping but not identical.

26 T cells ectopically expressing costimulators are pathogenic and contribute to autoimmun

27 cells possessed B7-2 genes and expressed the costimulators as surface molecules, we propose that T ce

28 n advantage of the strong CTL responses to a costimulator B7-1-transfected tumor to study the mechani

29 tory tract enhance surface expression of the costimulator B7-2 (CD86) within 24-48 h following infect

30 e modulation of the expression of the T cell costimulator B7-H2 by GECs.

31 Coexpression of the costimulator B7.1 and the Tag oncoprotein leads to destr

32 ritis, we found that KTC did not express the costimulators B7-1 or B7-2.

33 The costimulator, B7-2, was required for optimum activation

34 ressed, ICOS did not act as a general T cell costimulator but selectively caused a massive expansion

35 ot only can ICAM-1 act as a CD28-independent costimulator, but it is the dominant, requisite costimul

36 Human ECs do not express B7 costimulators, but Nef- replication in CD4(+)-T-cell and

37 s of T cell division in comparison to single costimulators, but rather enhanced accumulation in a cel

38 es that arming tumor-reactive T cells with a costimulator can enhance their antitumor efficacy.

39 eceptors were generated with CD28, inducible costimulator, CD134, or CD137 signaling regions in serie

40 Contemporaneously, the costimulator CD27 was down-regulated.

41 prosurvival effects of the TNF-R superfamily costimulator CD27.

42 potent than those mediated by the "classic" costimulator CD28.

43 Significantly, this "tetra-costimulator" combination, delivered intratumorally, ind

44 alteration of the same residue in inducible costimulator-containing (ICOS-containing) CAR-T cells re

45 Furthermore, several recently described costimulators contribute to these processes.

46 B-cell lymphoma 6, IL-21, inducible costimulator, CXCR5, and programmed cell death protein 1

47 tin-1 antagonizes Ag induced signals and TCR/costimulator dependent lipid raft clustering at the TCR

48 s with preformed conjugates of a murine B7-1 costimulator derivative, B7-1.Fc(gamma1), and pal-prot A

49 Strikingly, MRL-Faslpr mice lacking both B7 costimulators do not develop kidney (glomerular, tubular

50 Blockade of these costimulators each partially reduces IFN-gamma and IL-2

51 ibility complex (MHC) class II molecules and costimulators, EC-stimulated virus-producing cells (p24(

52 assays were used to evaluate the role of B7 costimulators expressed by CMFs with regard to the regul

53 New evidence shows that negative costimulators expressed by tumors and normal tissues aff

54 sion protein derivatives of three additional costimulators (Fc(gamma1).4-1BBL, CD48.Fc(gamma1), and F

55 molecule, a cell surface protein which is a costimulator for T cell activation.

56 like rhIL-4, rhIL-4 delta 2 did not act as a costimulator for T cell proliferation.

57 tions as a pathogen receptor and is a potent costimulator for the induction of interferon-gamma (IFN-

58 timulation and the relative importance of B7 costimulators for the induction and effector phases of e

59 into cell membranes by this method retained costimulator function, as measured by an in vitro prolif

60 led from signals that promote maturation and costimulator function.

61 We and others have proposed that costimulators function to construct a raft-based platfor

62 Thus, constitutively expressed B7 costimulators function to suppress T cell activation and

63 Various cytokines and costimulators have been identified which regulate expres

64 cytometry was used to measure CD69/inducible costimulator/HLA-DR frequency in memory cell subsets, as

65 ating signaling intensity from the inducible costimulator ICOS and kinase PI(3)K by suppressing expre

66 Signaling via the inducible costimulator ICOS fuels the stepwise development of foll

67 of CD40-ligand (CD40L) and inducible T-cell costimulator (ICOS) (both P < 0.001) and decreased produ

68 Inducible costimulator (ICOS) and B7-related protein-1 (B7RP-1) co

69 Interaction between inducible costimulator (ICOS) and its ligand is implicated in the

70 c T lymphocyte antigen 4 (CTLA-4), inducible costimulator (ICOS) and PD-1.

71 Using inducible costimulator (ICOS) as a model, we failed to find any pr

72 d chemokine receptor 5 (CXCR5) and inducible costimulator (ICOS) at low levels (CXCR5(lo)ICOS(lo)), a

73 h17 cells stimulated with alphaCD3/inducible costimulator (ICOS) beads produced more IL-17A, IFNgamma

74 ulating GC selection by increasing inducible costimulator (ICOS) expression on TFH cells and reducing

75 Inducible costimulator (ICOS) has been suggested to perform an imp

76 r and cooperation between CD28 and inducible costimulator (ICOS) in effective T helper (TH) cell resp

77 D1 to enhance expression of inducible T-cell costimulator (ICOS) in memory CD4(+) T cells from health

78 ells exhibit decreased and delayed inducible costimulator (ICOS) induction and heightened CD40L expre

79 T cells with a CAR containing the inducible costimulator (ICOS) intracellular domain generates tumor

80 Inducible costimulator (ICOS) is a new member of the CD28/CTLA-4 f

81 Inducible costimulator (ICOS) is a novel costimulatory receptor ex

82 The inducible T cell costimulator (ICOS) is a potent promoter of organ inflam

83 Inducible costimulator (ICOS) is a recently identified costimulato

84 Inducible T-cell costimulator (ICOS) is a specific marker of T-cell activ

85 Inducible costimulator (ICOS) is expressed on activated and memory

86 Expression of the inducible costimulator (ICOS) is increased in TSC1-deficient T cel

87 The inducible costimulator (ICOS) is the newest member of the CD28/CD1

88 Inducible costimulator (ICOS) is the third member of the CD28/CTLA

89 Inducible costimulator (ICOS) ligand (ICOSL), a B7-related transme

90 stigated whether EBNA2 affects the inducible costimulator (ICOS) ligand (ICOSL), a molecule required

91 rgely a result of up-regulation of inducible costimulator (ICOS) ligand on TACI-deficient B cells, gi

92 usly shown that 3 doses of an anti-inducible costimulator (ICOS) mAb transiently ameliorated symptoms

93 requency of T cells expressing the inducible costimulator (ICOS) molecule, a T-cell-specific molecule

94 B7h interacts with inducible costimulator (ICOS) on T cells and provides a positive s

95 The inducible costimulator (ICOS) plays a key role in the development

96 ellular interleukin 21 (IL-21) and inducible costimulator (ICOS) post vaccination; these responses we

97 We demonstrate that inducible costimulator (ICOS) provides a critical early signal to

98 igher levels of interleukin 10 and inducible costimulator (ICOS) than their lymph node counterparts.

99 s on the immune reaction of inducible T cell costimulator (ICOS)(+) ILC2 cells.

100 Inducible costimulator (ICOS), a CD28/cytotoxic T lymphocyte antig

101 Inducible costimulator (ICOS), a member of the CD28 family of cost

102 Inducible costimulator (ICOS), a member of the CD28 family of cost

103 le expressed on activated T cells, inducible costimulator (ICOS), and its ligand, B7-related protein-

104 Tpex cells highly express inducible costimulator (ICOS), but how ICOS modulates PD-1(+)CD8(+

105 -related marker, such as CTLA4 and inducible costimulator (ICOS), in the skin allograft and draining

106 escribed ligand-receptor pair, B7h-inducible costimulator (ICOS), is critical for germinal center for

107 whether a costimulatory receptor, inducible costimulator (ICOS), is involved in NK cell function, we

108 associated molecules IL-10, inducible T-Cell costimulator (ICOS), lymphocyte activation gene 3 protei

109 le of novel costimulatory molecule-inducible costimulator (ICOS), OX40, 4-1BB, and CD27 in mediating

110 g ICOSL, the ligand for the Inducible T cell costimulator (ICOS), thereby impairing the capacity of T

111 oding IcosL, the ligand for Inducible T-cell costimulator (Icos), thus impairing the ability of T cel

112 n a fashion dependent on IL-21 and inducible costimulator (ICOS), thus sharing fundamental characteri

113 gulation of CD40L, PD-1, and inducibl T-cell costimulator (ICOS), which may favor the accumulation of

114 Expression of inducible T cell costimulator (ICOS), which sustains Tfh function and phe

115 ata reveal the necessity of inducible T-cell costimulator (ICOS)-ICOS ligand cell contact for Treg ce

116 vent fibrosis is controlled by the inducible costimulator (ICOS)-ICOS ligand pathway.

117 lymphocyte antigen-4 (CTLA-4), and inducible costimulator (ICOS).

118 ally related proteins CD28 and the inducible costimulator (ICOS).

119 sion of bound target mRNAs such as inducible costimulator (Icos).

120 r CD4, CD25, Foxp3, and the inducible T cell costimulator (ICOS).

121 of Foxp3(+) Treg cells expressing inducible costimulator (ICOS).

122 d markedly increased expression of inducible costimulator (ICOS).

123 king mAbs for IL-21/IL-21R, inducible T-cell costimulator (ICOS)/ICOS ligand, and CD40L/CD40 hindered

124 leukin (IL)-17A(+) phenotype in an inducible costimulator (ICOS)/ICOS ligand-dependent manner.

125 A>G), Fas ligand (fasL, -844 C>T), inducible costimulator (ICOS, 3990 G>T), interleukin-6 (IL-6, -174

126 uired T-cell costimulation via the inducible costimulator (ICOS-ICOS-ligand pathway.

127 ed the greatest T-cell activation (inducible costimulator [ICOS]) and a broader immune phenotype with

128 yte-associated antigen 4 [CTLA-4], inducible costimulator [ICOS], program death-1 [PD-1], and B- and

129 ls and the binding is abrogated by inducible costimulator Ig (ICOSIg), but not CTLA4Ig.

130 ry response, we have both expressed a potent costimulator in oncogene-expressing beta cells and incre

131 revealed a requirement for the CD5 and CD28 costimulators in autoantigen-induced deletion.

132 ed strong evidence for the action of several costimulators in negative selection, we wished to demons

133 antibody to transiently block the inducible costimulator/inducible costimulator ligand (ICOS/ICOSL)

134 of costimulatory receptors (inducible T-cell costimulator, interleukin 7 receptor), whereas inhibitor

135 est that an extraordinarily complex array of costimulators is involved in negative selection.

136 pDCs upregulate the expression of inducible costimulator ligand (ICOS-L) and maintain high expressio

137 hat human melanomas express inducible T-cell costimulator ligand (ICOS-L/B7H) that can provide costim

138 y block the inducible costimulator/inducible costimulator ligand (ICOS/ICOSL) signaling pathway led t

139 were given isotype or anti-inducible T-cell costimulator ligand (ICOSL) antibodies and then challeng

140 novel renoprotective role for the inducible costimulator ligand (ICOSL) in early kidney disease thro

141 ptor regulate B-cell expression of inducible costimulator ligand (ICOSL), a molecule required for Tfh

142 entified ICOSLG, which encodes the inducible costimulator ligand (ICOSLG or ICOSL) as a susceptibilit

143 ll death-2 ligand [PD-L2]), CD275 (inducible costimulator ligand [ICOS-L]), CD276 (B7-H3), B7-H4, and

144 other immune regulatory molecules (inducible costimulator ligand and glucocorticoid-induced tumor nec

145 the response is completely inducible T-cell costimulator ligand independent.

146 the Bcl6 transcription factor and inducible costimulator ligand on B cells.

147 IL-27, IL-10, and inducible T-cell costimulator ligand signaling are essential for CD1c(+)D

148 f the cell-surface receptor inducible T-cell costimulator ligand that promotes optimal interactions b

149 mulatory molecules CD40 and inducible T cell costimulator ligand was significantly reduced in anti-BA

150 1-NIK axis and upregulates ICOS-L (inducible costimulator ligand) and PD-L2 (programmed death ligand

151 expression of activin A and inducible T-cell costimulator ligand.

152 h ligands, OX40 ligand, and inducible T-cell costimulator ligands were not implicated.

153 ation blockade using CD154 or anti-inducible costimulator mAb.

154 infections were multiple other cytokines and costimulators may be up-regulated.

155 els in CD4(+)/CD8(+) T cells, with inducible costimulator molecule and HLA-DR defining midterm and lo

156 rum from infancy to adulthood (eg, inducible costimulator molecule and IL-22).

157 adhesion, up-regulation of MHC class II and costimulator molecule expression, and acquisition of enh

158 CD40 ligand (CD40L) is a costimulator molecule that directly activates T cells an

159 However, lack of expression of conventional costimulator molecules means that these cells tend to in

160 ss-links multiple cell surface receptors and costimulator molecules on human T cells.

161 xpand in vivo, presumably due to the lack of costimulator molecules on tumor cells and the inherent l

162 ic beta cells, which do not normally express costimulator molecules, converts the cells into effectiv

163 ession of peptide-class II MHC complexes and costimulator molecules.

164 uman B7-H3 was first described as a positive costimulator, most potently inducing IFN-gamma productio

165 Several recently identified costimulators, namely, 4-1BB ligand, ICOS ligand, and OX

166 cordingly, we examined thymocyte deletion in costimulator-null mice in three models of autoantigen-in

167 yte stimulator (BLyS) is a well-known direct costimulator of adaptive immune cells, particularly B li

168 on of TS1 in platelets is that of a secreted costimulator of alphaIIbbeta3 whose unique properties re

169 Therefore, 2B4 functions as a costimulator of CD8(+) T cells in MHC-restricted cytotox

170 gen 6alpha3 to produce endotrophin, a potent costimulator of fibrosis and inflammation.

171 These data identify CD55 as a novel costimulator of human Tr1s and support a role for altern

172 1A is a novel TNF-like factor that acts as a costimulator of IFN-gamma secretion through binding to t

173 of an agonist antibody to CD40, an important costimulator of immune function, in combination with int

174 Flt3/flk-2 ligand (flt3-L) is a potent costimulator of normal bone marrow (BM) myeloid progenit

175 s ligand is therefore an inducer of death, a costimulator of peripheral T cell activation, and an acc

176 We show that thalidomide is a potent costimulator of primary human T cells in vitro, synergiz

177 IL-12, a costimulator of Th1 having no proliferation-inducing cap

178 was a concomitant response to IL-1, a known costimulator of Th2.

179 Our data designate CXCR4 as a costimulator of the pre-TCR during beta-selection.

180 Adenosine is an important costimulator of yd T cell activation, which is essential

181 roducers of IgG1, IgG2a, and IgG2b, and weak costimulators of CD4(+) Tconv proliferation.

182 Moreover, circulating monocytes were potent costimulators of IL-9 production by Th17 cells via their

183 TNFRSF4 agonists were potent costimulators of OVA/aluminum hydroxide-induced CD4(+) T

184 he TNF receptor superfamily (TNFRSF) are key costimulators of T cells during infection, and there has

185 ction, whereas TNFRSF25 agonists were strong costimulators of Treg proliferation, producers of IgG1,

186 tegy to establish that the levels of surface costimulator on APCs can dictate both the magnitude and

187 Here we show that SLAMF3 functions as a costimulator on CD4(+) T cells and influences IL-2 respo

188 especially upregulation of inducible T-cell costimulator on T cells, together with severely disturbe

189 ntigens, we hypothesize that neoexpressing a costimulator on tumor-reactive T cells may likewise enha

190 ts T cell function by acting as an intrinsic costimulator or by induction of other costimulatory mole

191 Inclusion of CD28, inducible costimulator, or CD134 enhanced TCRzeta-mediated, Ag-spe

192 novirus Delta-24-RGDOX expressing the immune costimulator OX40 ligand (OX40L).

193 ternative costimulatory receptors (inducible costimulator, OX40, 4-1BB, cytotoxic T lymphocyte associ

194 ly impaired upregulation of inducible T-cell costimulator, OX40, cytokine production, proliferation o

195 increased T-cell expression of the negative costimulator PD-1 recently has been postulated to contri

196 IL-35 production by inducible costimulator-positive Treg cells can suppress IL-17 prod

197 cell activation by class II MHC antigens and costimulators (principally lymphocyte function-associate

198 dy, we reveal a crucial role of the negative costimulator programmed death-1 (PD-1) in regulating dev

199 The CD28 family member inducible costimulator protein (ICOS) has an important role in T c

200 cation of the B7-related protein 1/inducible costimulator protein (ICOS) pathway and its ability to r

201 tion of antitumor immunity via combinatorial costimulator protein transfer on to tumor cell surfaces.

202 The notion of costimulator receptor activation thresholds emerges.

203 In this study, we find that the 4-1BB costimulator receptor, best known for promoting the prol

204 mparable activation thresholds exist for the costimulator receptors on T cells.

205 pendent upon coordinate engagement of Ag and costimulator receptors on their surfaces.

206 l-costimulatory molecules CD28 and inducible costimulator recruit and activate class 1A phosphoinosit

207 y of anti-tumor necrosis factor agents and a costimulator signal inhibitor.

208 eas CD40/CD40L interactions provide critical costimulator signals for T-cell-dependent immune respons

209 lability of IL-2, and accessory cell or CD28 costimulator signals.

210 It is reported that the CD86 costimulator significantly affects disease outcome in Le

211 tion gene 3 and low CD3/CD4/inducible T-cell costimulator specifically in the tumor center as associa

212 gh PD-1 can overcome the ability of positive costimulators, such as CD2 and CD28, to facilitate posit

213 nt finding that thalidomide acts as a T cell costimulator suggested that this drug may boost antivira

214 d the frequency of ICOS(+) (inducible T-cell costimulator) Tfh-like cells in blood.

215 actor (TNF)-like cytokine (TL1A) is a T-cell costimulator that bolsters cytokine-induced activation t

216 e results identify IL-15 as an indispensable costimulator that can determine the functional fate of a

217 Interestingly, in T cells, TL1A acts as a costimulator that increases IL-2 responsiveness and secr

218 encompassing immune checkpoint blockers and costimulators that functionally oligomerize in vivo with

219 nistic analysis of a newly emerging group of costimulators, the TNF family.

220 ent years by the identification of different costimulators, this classical pathway has been shown to

221 induce T-cell proliferation alone but act as costimulators to trigger proliferation of anti-CD3-stimu

222 We now show that in the absence of costimulators, TRAIL induction on pDCs occurs with agoni

223 Hence, combinatorial costimulator transfer, coupled to intratumoral delivery,

224 B7-H2, best known as the ligand of inducible costimulator, was a ligand for CD28 and CTLA-4 in human,

225 We predict that different sets of costimulators will be required depending on the timing o

226 t of autoimmunity, and functions as a potent costimulator with antiimmunoglobulin M in B cell prolife

227 is review, we will discuss this new class of costimulators with a focus on the mechanism of costimula